PubMed Health⌕ Search

Biomedical subjects

R Pifarré

Publications and source records attributed to R Pifarré.

At least 37 records · Page 2Linked to original sources
PubMed1994

Disruption of sutured pulmonary valve in Fontan operation.

Two patients who had undergone a Fontan operation presented late with considerable disruption of a sutured pulmonary valve. Both patients had increasing ascites, decreased exercise tolerance, atrial arrhythmias, high right atrial pressure, and a large ratio of pulmonary blood flow to systemic blood flow. At operation, the main pulmonary artery was closed either by suturing the anterior and posterior walls together immediately distal to the pulmonary valve or by reinforcing the resutured pulmonary valve with a polytetrafluoroethylene patch. Both patients had an uneventful postoperative course, with disappearance of the symptoms and return of sinus rhythm. Although it is tempting to simply suture the usually thickened pulmonary valve in the Fontan operation, approximation of the pulmonary artery walls or patch reinforcement is necessary to minimize disruption.

Adult↗
PubMed1993

Surgical techniques in partial anomalous pulmonary veins to the superior vena cava.

Over a 12-year period, 40 patients underwent repair of partial anomalous pulmonary veins (PAPV) draining to the superior vena cava (SVC) proximal to the sinus node. Mean age was 6 +/- 2 years. In all patients, the SVC was cannulated superior to the PAPV, which were baffled with pericardium to left atrium. Six patients had associated defects repaired. In 18 patients (group I), an incision was made at the crest of the right atrial appendage (RAA) and extended upward through the sinus node and to the SVC. After rerouting of the PAPV, the SVC was enlarged using the RAA (atriocavoplasty). In 17 patients (group II), rerouting of the PAPV was accomplished through a right atriotomy. Superior vena caval enlargement was not done. Drainage of the PAPV was close to the right atrium in 14 patients (low) and to the azygos vein (high) in 3. In 5 patients (group III), an incision was made on the SVC and RAA sparing the sinus node. After rerouting of the PAPV, the RAA was anastomosed to the SVC (end to side), providing another outlet for SVC flow. There was no early or late death. Two patients (10%) in group I had late sinus bradycardia. Obstruction of the SVC and PAPV developed in 1 patient in group II with high drainage. Intermittent complete heart block developed in 1 patient in group III who also had ventricular septal defect repair. We conclude that atriocavoplasty is effective for rerouting of the PAPV and enlarging the SVC, but may predispose to sinus node disease.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗
PubMed1993

High-risk cardiac operation: a viable alternative to heart transplantation.

To determine if high-risk heart operation with circulatory support standby is an acceptable alternative to direct heart transplantation, we reviewed 21 patients who were accepted as heart transplant candidates but offered a heart operation because of the availability of circulatory support. Preoperative left ventricular ejection fraction was 0.25 +/- 0.08 (mean +/- standard deviation), and New York Heart Association functional class was 3.4 +/- 0.7. The patients underwent 16 bypass graft operations, 4 mitral and 2 aortic valve replacements, and 4 defibrillator implantations (combined procedures in 5 patients). An intraaortic balloon pump was placed in 12 patients. One patient required biventricular assist device support but was weaned in 11 days. Twenty patients were discharged 14.8 +/- 11.5 days postoperatively. One patient died 15 days postoperatively of amiodarone-induced respiratory failure, and 1 died suddenly 2 months postoperatively. At 10.5 +/- 6 months postoperatively, 19 patients (90%) are alive. Mean functional class is 1.9 +/- 0.9. None of the patients has undergone transplantation, but 2 are awaiting donor organs. We conclude that in selected heart transplant candidates high-risk heart operation is a viable alternative to direct heart transplantation.

Actuarial Analysis↗
PubMed1993

Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery.

This study was designed to evaluate anticoagulant monitoring of heparin and platelet function in the presence of aprotinin. Aprotinin added to heparinized whole blood at concentrations equal to (30 micrograms/mL), twice, and four times that used in cardiopulmonary bypass operations synergistically elevated the activated clotting time (ACT) (536 +/- 73, 651 +/- 86, and 787 +/- 71 seconds, respectively) over the value with heparin alone (384 +/- 66 seconds) (p < 0.001). In addition, the ACT of heparin-aprotinin mixtures supplemented with protamine showed that the heparin was not completely neutralized (131 +/- 12 versus 98 +/- 7 seconds). Specific tests revealed that the effect on ACT caused by aprotinin is not equal to the anticoagulant effect of heparin. Thus there is a risk of under-heparinization if the ACT is used as a monitor when aprotinin is present. Furthermore, protamine doses relative to the heparin concentration, and not relative to the ACT, should be used to reverse heparin. In studying the effects of aprotinin on platelet function, there was a significant inhibition of aggregation when normal platelets were supplemented with aprotinin, but not for platelets of postoperative patients. This suggests that aprotinin may interact more favorably with nonactivated platelet surfaces, reducing or inhibiting the expression of receptors. Thus it is necessary to treat a patient with aprotinin before beginning cardiopulmonary bypass. Based on these data, the effect of aprotinin on the hemostatic system and its drug interactions must be considered to optimize safety and efficacy during cardiopulmonary bypass operations.

Aprotinin↗
PubMed1993

Right ventricle-to-aorta conduit in pulmonary atresia with intact ventricular septum and coronary sinusoids.

A 20-month-old girl with pulmonary atresia, intact ventricular septum, and ventriculocoronary connections underwent successful interposition of a right ventricle-to-aorta conduit and Fontan operation. The patient initially had a modified Blalock-Taussig shunt at birth and subsequently a bidirectional Glenn shunt at 8 months of age. After Fontan and right ventricle-to-aorta conduit placement, the suprasystemic right ventricular pressure dropped to systemic levels without causing myocardial injury. Additionally, the right ventricular cavity enlarged. We believe that the use of a right ventricle-to-aorta conduit should provide a valuable alternative and improve the outlook of certain patients with pulmonary atresia, intact ventricular septum, and ventriculocoronary connections.

Cardiac Surgical Procedures↗
PubMed1993

Obligatory Glenn shunt in fenestrated Fontan.

Five high-risk patients undergoing the Fontan operation required large fenestration (1 cm) because of high central venous pressure and low cardiac output. Because of major arterial desaturation, obligatory Glenn shunts were performed. Three patients had pulmonary atresia, 1 had tricuspid atresia 1-B, and the fifth had single ventricle with subaortic stenosis. The age ranged from 16 to 40 months (mean age, 25 +/- 9 months) and weight from 7.9 to 14.6 kg (mean weight, 11 +/- 2 kg). One patient had single and 3 had bilateral subclavian pulmonary artery shunts. The fifth patient had pulmonary artery banding and coarctation repair followed by an aortopulmonary window and central shunt. The first 2 patients repeatedly had to go back on cardiopulmonary bypass for a larger fenestration and subsequently had an obligatory Glenn shunt because of arterial desaturation. The last 3 patients had planned obligatory Glenn shunt and large fenestration. The first patient died on the second postoperative day of a combination of prolonged operation, repeated cardiopulmonary bypass, and periods of hemodynamic instability. Three patients had closure of the adjustable fenestration under local anesthesia at 4, 5, and 8 weeks postoperatively. The last patient is awaiting closure. We believe that in certain high-risk patients, a large fenestration combined with an obligatory Glenn shunt should be considered to minimize repeated cardiopulmonary bypass and urgent tightening or closure of fenestration in the immediate postoperative period.

Arteriovenous Shunt, Surgical↗
PubMed1993

Open heart operations in the elderly: changing risk parameters.

Greater numbers of people are living longer, causing a concurrent change in the population of patients who require open heart operations. One question that needs to be addressed is the effect of age on surgical outcome. Current statistics suggest that in 15 to 20 years there will be 12 million people in the United States more than 80 years of age. We examined risk factors for outcome in two retrospective studies of advanced-age patients requiring cardiac operations. The first group of 100 patients more than 75 years of age had valve replacement. Early mortality was acceptable at 3%. However, mortality at 2 years increased to about 25%, due largely to complications related to anticoagulation. Quality of life was dramatically improved in survivors. These data suggest that implantation of a tissue valve may be the most beneficial option in patients aged more than 70 years. In the second group, we used multivariate analysis to define the factors contributing to early mortality in 133 patients aged 80 years or older who required cardiac operations from 1988 to 1990. This analysis showed that early mortality increased significantly in patients in New York Heart Association class IV or in those who required postoperative blood transfusion. These data suggest the need to prevent excessive bleeding and to assess patients on an individual basis.

Aged↗
PubMed1993

Nonthoracotomy lead system for implantable defibrillator.

Over a 2-year period, 110 patients underwent attempted implantation of an automatic cardioverter-defibrillator using the nonthoracotomy lead system. Indications included sustained monomorphic ventricular (n = 62), nonsustained with poor ventricular function (n = 7), ventricular fibrillation (n = 21), ventricular tachycardia/fibrillation (n = 18), and familial long QT syndrome (n = 2). There were 90 male and 20 female patients. Mean age was 57 +/- 15 years. Sixty percent had previous coronary bypass or valve operations, or both. Mean left ventricular ejection fraction was 30% +/- 14%, cardiac index was 2.4 +/- 0.9 L/m2, and systolic pulmonary artery pressure was 41 +/- 14 mm Hg. Under general anesthesia, the nonthoracotomy lead was introduced through the left subclavian vein. The subcutaneous patch and generator were placed posteriorly on the serratus muscle and left upper quadrant, respectively. The length of the procedure was 116 +/- 44 minutes and the mean number of defibrillation shocks for a successful implant was 8 +/- 4. Eighty-five patients (77%) had successful implantations. Failures were due to high defibrillation threshold (n = 23) and inability to place a right ventricular lead (n = 2). Predictors of failure included preoperative antiarrhythmic drugs and cardiac index of 1.8 +/- 4 L/m2 or less (p = 0.004). Three patients (2.7%) died after the operation of heart failure (n = 2) and chronic heart transplant rejection (n = 1). Complications included lead migration or dislodgment (n = 8), infection (n = 1), and hematoma (n = 3). In summary, the nonthoracotomy lead system may provide an alternative in patients undergoing cardioverter-defibrillator implantation.

Aged↗
PubMed1992

Hemostatic abnormalities in total artificial heart patients as detected by specific blood markers.

We retrospectively evaluated the hemostatic system of 13 patients during implantation (2 to 35 days) of the Jarvik 7-70 total artificial heart (TAH). Although all patients were clinically manageable while on the TAH, 5 had excessive generalized bleeding. After the heart transplant procedure, 2 patients had neurological events and 1 patient, thrombosis of the leg. While the patients were supported by the TAH, the routine coagulation assays (prothrombin time, activated partial thromboplastin time, fibrinogen, factor assays, and platelet count) showed slight abnormalities but no correlation to hemorrhagic or thrombotic events. In contrast, plasma and cellular activation markers, which are highly sensitive and specific for hypercoagulability, fibrinolysis, or platelet activation, revealed activation in all patients. Most striking was the marked activation of the fibrinolytic system (p less than 0.05 to 0.001). Correlations of individual patient data compared with the average TAH group response could be made between excessive enhancement of fibrinolysis (increased D-dimer and tissue plasminogen activator and decreased plasminogen activator inhibitor) and bleeding. A hypercoagulable state (increased fibrinogen and thrombin-antithrombin complex and decreased antithrombin III and protein C), decreased fibrinolysis (decreased tissue plasminogen activator and D-dimer), activated platelets (increased thromboxane B2), or combinations of these were associated with thrombosis. The hemostatic activation returned to normal 1 day after removal of the TAH. These data suggest that the patient with a TAH requires more sophisticated laboratory monitoring and individualized treatment for excessive fibrinolysis, hypercoagulable state, or platelet activation to avoid thrombotic and hemorrhagic complications.

6-Ketoprostaglandin F1 alpha↗
PubMed1990

Surgical ablation of ventricular tachycardia in the normothermic heart.

Nineteen patients with ventricular tachycardia were subjected to surgery using a normothermic map-guided approach. Surgical ablation was performed by endocardial resection and cryoablation. Eleven patients had multiple distinct morphologies, and eight patients needed concomitant coronary artery bypass surgery. Seventeen patients survived the perioperative period, and all but one patient had a successful surgical ablation of all documented morphologies. Ventricular tachycardia surgery can be accomplished with the sequential map-guided approach on the normothermic beating heart, and in this era of the implantable defibrillator should remain a mainstay of the surgical treatment for ventricular tachycardia.

Aged↗
PubMed1989

Ventricular aneurysm due to blunt chest injury.

A left ventricular aneurysm developed in 3 patients sustaining blunt chest injury. Evidence of an acute myocardial infarction on the electrocardiogram and enzyme analysis prompted cardiac catheterization, which revealed total occlusion of the left anterior descending coronary artery in 2 of the 3 patients. Ventricular aneurysmectomy was performed in each patient. A review of the literature revealed 32 previously reported patients with left ventricular aneurysm caused by blunt trauma. Clinical features, catheterization or autopsy findings, and outcome are examined.

Adult↗
PubMed1989

Pacing lead fracture after a deceleration injury.

Acute pacemaker malfunction is potentially lethal. A high index of suspicion must be maintained in physicians caring for traumatized patients utilizing permanent pacing systems. We present a case of transvenous pacemaker lead fracture sustained in a vehicular deceleration injury.

Accidents, Traffic↗
PubMed1989

Predicting need for surgical drainage of pericardial effusion in patients with end-stage renal disease.

The best approach to treatment of pericarditis accompanied by substantial pericardial effusion in end-stage renal disease (ESRD) patients is unknown. In a review of our experience, we found that ESRD patients with moderate-to-large or large (circa 250 mL or larger) pericardial effusions usually failed to improve with intensive dialysis and ultimately required surgical drainage of the effusion. Multivariate analysis revealed that effusion size was by far the most important factor predicting need for surgery. Since early pericardial drainage obviates the risk of sudden tamponade, we recommend that surgery without prior intensive dialysis therapy be considered in such patients.

Drainage↗
PubMed1989

Predictors of late acute orthotopic heart transplant rejection.

To identify predictors of late acute rejection after orthotopic heart transplantation (OHT), 53 patients who received transplants between March 1984 and March 1987 and who survived at least 1 year postoperatively were followed up for 402-1,151 days (mean, 841 days). Fourteen patients experienced 22 moderate or severe rejection episodes more than 1 year after OHT (LR); 39 were nonrejectors (NR). Twelve of 14 (86%) LR and only 14 of 39 (36%) NR had two or more moderate or severe rejection episodes within the first year after OHT (p less than 0.001). The LR had significantly higher numbers of infections more than 1 year after OHT (2.0 vs. 0.9; p less than 0.05). Nine of 22 (40%) late acute rejection episodes followed within 1 month of infection. Human leukocyte antigen reactivity before OHT, follow-up hemodynamics, length of survival, incidence of diabetes mellitus, coronary artery disease 1 year after OHT, mean cyclosporine levels, and mean daily prednisone doses were similar in LR and NR patients. We conclude that 1) OHT recipients with two or more moderate or severe rejection episodes in the first year after OHT are at higher risk of developing late acute rejection and may require closer long-term rejection surveillance and more aggressive maintenance immunosuppression and 2) the possible relation between infection and subsequent acute rejection episodes in OHT recipients requires further investigation.

Adult↗
PubMed1989

Results of the first 100 patients who received Symbion Total Artificial Hearts as a bridge to cardiac transplantation.

Between August 8, 1985 and April 1, 1988, 100 patients in 22 centers underwent Symbion Total Artificial Heart (TAH) (Symbion, Inc., Salt Lake City, Utah) implantation as a bridge to cardiac transplant. Thirty patients received the Symbion J7-100, and 70 patients received Symbion J7-70 implants. Eighty-seven patients were men and 13 were women; mean age was 42 years, and mean weight was 73 kg. The time spent on the device ranged from 1 to 243 days, for a mean of 23 days. Sixty-eight patients underwent cardiac transplantation, with a 69% 30-day survival rate and a 46% (31 of 68) long-term survival rate. The majority of the patients had ischemic (52) or idiopathic (36) cardiomyopathies. Indications for implantation of the TAH occurred most frequently in patients whose condition deteriorated while awaiting transplant (34) or who were admitted in acute cardiogenic shock (27). There was an 8.7% incidence of thromboembolic events (four cerebrovascular accidents, five transient ischemic attacks). Multivariant analysis was performed to determine the effect of various factors on the patients' ability to undergo transplantation and then ultimate survival. The results indicate a need for further clinical investigation in patient selection and appropriate timing for implantation of the TAH.

Adult↗